TY - JOUR
T1 - Active commuting and the risk of obesity, hypertension and diabetes
T2 - A systematic review and meta-analysis of observational studies
AU - Wu, Jian
AU - Li, Quanman
AU - Feng, Yu
AU - Bhuyan, Soumitra S.
AU - Tarimo, Clifford Silver
AU - Zeng, Xin
AU - Wu, Cuiping
AU - Chen, Ning
AU - Miao, Yudong
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2021/6/25
Y1 - 2021/6/25
N2 - Active commuting may hold a potential for preventing adverse health outcomes. However, evidence of the association of active commuting and the risk of health outcomes remains debatable. The current study systematically and quantitatively summarised research findings on the association between active commuting and the risk of the mentioned health outcomes. We comprehensively searched four databases (PubMed, EMBASE, Web of Science and Open Grey) from inception to 2 August 2020 for observational studies investigating the associations among adult population. Summary relative risks (RRs) and 95% CIs were estimated for the association. Heterogeneity was investigated using Cochran's Q test and the I 2 statistic. Restricted cubic splines were used to evaluate linear and nonlinear relations. The search yielded 7581 initial references. We included 28 articles in the meta-analysis. Compared with inactive commuting, active commuting reduced the risk of obesity (RR=0.88, 95% CI 0.83 to 0.94, I 2 =69.1%), hypertension (RR=0.95, 95% CI 0.87 to 1.04, I 2 =82.2%) and diabetes (RR=0.82, 95% CI 0.76 to 0.90, I 2 =44.5%). Restricted cubic splines showed linear associations between active commuting and obesity, hypertension and diabetes (P nonlinearity =0.640; P nonlinearity =0.886; P nonlinearity =0.099). As compared with the lowest active commuting group, the risk of obesity, hypertension and diabetes in the highest active commuting group were reduced by 13% (95% CI 0.82 to 0.93, I 2 =65.2%); 6% (95% CI 0.86 to 1.02, I 2 =75.2%) and 19% (95% CI 0.73 to 0.91, I 2 =49.8%) respectively. Active commuting seemed to be associated with lower risk of obesity, hypertension and diabetes. However, the results should be interpreted cautiously because this meta-analysis was based solely on observational studies. PROSPERO registration number CRD42020202723.
AB - Active commuting may hold a potential for preventing adverse health outcomes. However, evidence of the association of active commuting and the risk of health outcomes remains debatable. The current study systematically and quantitatively summarised research findings on the association between active commuting and the risk of the mentioned health outcomes. We comprehensively searched four databases (PubMed, EMBASE, Web of Science and Open Grey) from inception to 2 August 2020 for observational studies investigating the associations among adult population. Summary relative risks (RRs) and 95% CIs were estimated for the association. Heterogeneity was investigated using Cochran's Q test and the I 2 statistic. Restricted cubic splines were used to evaluate linear and nonlinear relations. The search yielded 7581 initial references. We included 28 articles in the meta-analysis. Compared with inactive commuting, active commuting reduced the risk of obesity (RR=0.88, 95% CI 0.83 to 0.94, I 2 =69.1%), hypertension (RR=0.95, 95% CI 0.87 to 1.04, I 2 =82.2%) and diabetes (RR=0.82, 95% CI 0.76 to 0.90, I 2 =44.5%). Restricted cubic splines showed linear associations between active commuting and obesity, hypertension and diabetes (P nonlinearity =0.640; P nonlinearity =0.886; P nonlinearity =0.099). As compared with the lowest active commuting group, the risk of obesity, hypertension and diabetes in the highest active commuting group were reduced by 13% (95% CI 0.82 to 0.93, I 2 =65.2%); 6% (95% CI 0.86 to 1.02, I 2 =75.2%) and 19% (95% CI 0.73 to 0.91, I 2 =49.8%) respectively. Active commuting seemed to be associated with lower risk of obesity, hypertension and diabetes. However, the results should be interpreted cautiously because this meta-analysis was based solely on observational studies. PROSPERO registration number CRD42020202723.
KW - Diabetes
KW - Epidemiology
KW - Public health
UR - http://www.scopus.com/inward/record.url?scp=85108876643&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108876643&partnerID=8YFLogxK
U2 - 10.1136/bmjgh-2021-005838
DO - 10.1136/bmjgh-2021-005838
M3 - Article
AN - SCOPUS:85108876643
SN - 2059-7908
VL - 6
JO - BMJ Global Health
JF - BMJ Global Health
IS - 6
M1 - e005838
ER -